In cancer, pharmacological AMPK activation has been reported to protect against cachexia progression, as administration of the AMPK activator, 5‐aminoimidazole‐4‐carboxamide ribonucleotide (AICAR), prevented body weight loss, together with reduced muscle wasting and induction of the atrogenes Atrogin1 and Murf1 in cachectic tumour‐bearing mice.34, 35. Here, FBXO32 is linked to neoplasm.